Good corporate governance and high standards of ethical conduct are essential to the success of Idorsia Switzerland and to maintaining the trust of our stakeholders. The company's corporate governance aims to promote long-term relationships with all involved parties, uphold internal checks and balances, strengthen corporate accountability, and encourage responsible decision-making.

The Business Code of Conduct we adhere to supports our commitment to integrity and sets out the fundamental standards for interacting with others as we drive our business forward. Policies, standard operating procedures, and guidelines provide further detail on how our top-level commitments should be applied in practice. Compliance with this Code is mandatory, and all company employees receive training on its implementation.

We recognize that clinical trials are essential for the development of innovative medicines. At Idorsia Switzerland, we are committed to the highest standards of quality and ethics throughout our clinical research. Our trials are conducted in accordance with internationally accepted guidelines, and before any study begins, protocols are reviewed by independent review boards and ethics committees.

We also aim to improve public health through the responsible and transparent use of clinical trial data, while respecting proprietary information, patient privacy, applicable laws, and regulations. In addition, we are committed to implementing the Principles for Responsible Clinical Trial Data Sharing, jointly published by the European Federation of Pharmaceutical Industries and Associations (EFPIA) and the Pharmaceutical Research and Manufacturers of America (PhRMA).

More information

Learn more about our responsibilities on our corporate website.